If authorized, molnupiravir would be the first antiviral pill for treating COVID-19.
Earlier this month, Merck said molnupiravirreduces the risk of hospitalization or death by roughly half.
The pandemic haskilled more than 4.8 million people worldwide, including over 700,000 in the US.
